Affymetrix Redefines Association Studies with Introduction of SNP 5.0 Array
January 08 2007 - 3:00PM
Business Wire
Affymetrix Inc. (NASDAQ:AFFX) announced today that its new
single-chip SNP 5.0 Array was made available as a limited release
in December. The new array features single nucleotide polymorphisms
(SNPs) from the original two-chip 500K Array Set, as well as
500,000 additional probes that can measure other genetic
differences, such as copy number variation. The SNP 5.0 Array gives
researchers a significant increase in information above the
original 500K Array Set for the same price, while reducing the
array processing time. The Affymetrix SNP 5.0 Array was developed
in collaboration with the Broad Institute of Harvard and the
Massachusetts Institute of Technology to better identify and
understand the genetic variations associated with complex diseases
such as autism, autoimmunity, bipolar disease, cancer, diabetes and
heart disease. Scientists from the Autism Consortium and the Broad
Institute are using the SNP 5.0 Array to perform the most
comprehensive study to date on the genetics of autism. �To
understand the causes of complex genetic diseases, our
investigators want simultaneously to test both SNPs and copy number
variants, all in the same experiment.�The new Affymetrix SNP 5.0
Array makes this possible, integrating what had previously required
two separate technologies," said David Altshuler, M.D., Ph.D.,
director of the Program in Medical and Population Genetics at
Broad.�"The SNP 5.0 Array not only draws on the most current data
from the International HapMap Project to guide SNP assay design,
but also from the rapidly emerging database of common copy number
variants to direct placement of additional probes." �The Affymetrix
SNP 5.0 Array is a perfect example of how the power of GeneChip�
technology is helping to drive discovery,� said Richard Rava,
Ph.D., senior vice president, Research and Development at
Affymetrix. �The SNP 5.0 Array is enabling scientists to see more
information and increase the genetic power of their experiments to
get results faster.� The SNP 5.0 Array will be commercially
available by the end of the first quarter of 2007. Affymetrix is
working with scientists from the Broad Institute to develop
additional software tools for data analysis for the SNP 5.0 Array,
as well as add additional SNPs to the next-generation SNP 6.0 Array
that is scheduled to launch later this year. The SNP 5.0 Array is
the most recent addition to Affymetrix� line of genotyping
products, including the 10K, 100K and 500K Arrays, which are all
based on the proven Whole-Genome Sampling Assay. This technology is
being used by more than 200 laboratories and has generated data for
more than 150 peer-reviewed scientific publications. For more
information on recent discoveries using Affymetrix genotyping
products, please visit: Researchers Uncover Key Pathways Behind
ALS: http://www.microarraybulletin.com/community/article.php?p=286
Researchers Discover Gene Contributing to Human Memory Performance:
http://www.microarraybulletin.com/community/article.php?p=263
Researchers Discover Genetic Variant Associated with Obesity in
Humans: http://microarraybulletin.com/community/article.php?p=133
Researchers Discover a New Susceptibility Gene for Juvenile
Diabetes:
http://www.microarraybulletin.com/community/article.php?p=203 About
Affymetrix Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip�
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,400 systems have been installed around the
world and more than 7,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass., and Singapore. The company maintains important
sales and marketing operations in Europe and Asia, and has about
1,100 employees worldwide. For more information about Affymetrix,
please visit the company's website at www.affymetrix.com. All
statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected,
including, but not limited to: risks and uncertainties associated
with the success of the SNP 5.0 Array discussed in this press
release; risks of the Company's ability to achieve and sustain
higher levels of revenue, higher gross margins, reduced operating
expenses; uncertainties relating to technological approaches,
manufacturing, product development; personnel retention;
uncertainties related to cost and pricing of Affymetrix products;
dependence on collaborative partners; uncertainties relating to
sole source suppliers; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005, and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo
and GeneChip are registered trademarks owned or used by Affymetrix
Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024